RNAC logo

RNACSelecta Biosciences Inc

$7.43
$0.58
(8.47%)
Today
Closed $7.43
$0.04
(0.54%)
After Hours
Updated: 07:55 PM EDT
EarningsAug 6
Mkt Cap$201.26M
Vol545,692.00
News
all
press releases
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
Cartesian Therapeutics gains after licensing an in vivo CAR-T platform from WestGene, with a myasthenia gravis trial planned for 2026.read more...
Benzinga
News Placeholder
More News
News Placeholder
Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)
Wedbush restated an "outperform" rating and set a $38.00 price objective on shares of Cartesian Therapeutics in a research report on Friday...
MarketBeat
News Placeholder
Cartesian Therapeutics (NASDAQ:RNAC) Posts Quarterly Earnings Results
Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($1.46) earnings per share for the quarter, missing analysts' consensus...
MarketBeat
News Placeholder
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates
Cartesian Therapeutics, Inc. (RNAC) delivered earnings and revenue surprises of -73.81% and -81.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Cartesian Therapeutics (RNAC) Projected to Post Earnings on Thursday
Cartesian Therapeutics (NASDAQ:RNAC) will be releasing earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-selecta-biosciences-inc-stock-1...
MarketBeat
News Placeholder
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has received an average rating of "Moderate Buy" from the six brokerages that are covering the stock, Marketbeat reports. One equities...
MarketBeat
News Placeholder
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
News Placeholder
Cartesian Therapeutics (NASDAQ:RNAC) Trading 10.3% Higher - Time to Buy?
Cartesian Therapeutics (NASDAQ:RNAC) Shares Up 10.3% - What's Next...
MarketBeat
News Placeholder
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are covering the stock, MarketBeat Ratings reports. One...
MarketBeat
News Placeholder
Cartesian Therapeutics' (RNAC) "Outperform" Rating Reiterated at Wedbush
Wedbush restated an "outperform" rating and issued a $38.00 price target on shares of Cartesian Therapeutics in a research report on Tuesday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.